Interplay between programmed death-ligand 1 and non-coding RNAs

Programmed death-ligand 1 (PD-L1) is a transmembrane protein with essential roles in the suppression of adaptive immune responses. As an immune checkpoint molecule, PD-L1 can be exploited by cancer cells to evade the anti-tumor attacks initiated by the immune system. Thus, blockade of the PD1/PD-L1 axis can eliminate the suppressive signals and release the antitumor immune responses. Identification of the underlying mechanisms of modulation of the activity of the PD1/PD-L1 axis would facilitate the design of more efficacious therapeutic options and better assignment of patients for each option. Recent studies have confirmed the interactions between miRNAs/lncRNAs/circ-RNAs and the PD1/PD-L1 axis. In the current review, we give a summary of interactions between these transcripts and PD-L1 in the context of cancer. We also overview the consequences of these interactions in the determination of the response of patients to anti-cancer drugs.

[1]  Zhengxin Cai,et al.  Histone Methyltransferase SETDB1 Promotes Immune Evasion in Colorectal Cancer via FOSB-Mediated Downregulation of MicroRNA-22 through BATF3/PD-L1 Pathway , 2022, Journal of immunology research.

[2]  Weiwei Tang,et al.  Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma , 2022, Journal of oncology.

[3]  Xinwei Qiao,et al.  Long non-coding RNA Opa interacting protein 5-antisense RNA 1 binds to micorRNA-34a to upregulate oncogenic PD-L1 in non-small cell lung cancer , 2022, Bioengineered.

[4]  Yuan Gao,et al.  Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a. , 2022, The Tohoku journal of experimental medicine.

[5]  Mei Liu,et al.  Serum exosomal miR‐16‐5p functions as a tumor inhibitor and a new biomarker for PD‐L1 inhibitor‐dependent immunotherapy in lung adenocarcinoma by regulating PD‐L1 expression , 2022, Cancer medicine.

[6]  M. Taheri,et al.  Interplay Between Non-Coding RNAs and Programmed Cell Death Proteins , 2022, Frontiers in Oncology.

[7]  Yan Luo,et al.  HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis , 2021, Journal of immunology research.

[8]  M. Taheri,et al.  Regulatory Role of Non-Coding RNAs on Immune Responses During Sepsis , 2021, Frontiers in Immunology.

[9]  Yun Li,et al.  MicroRNA-889-3p restrains the proliferation and epithelial–mesenchymal transformation of lung cancer cells via down-regulation of Homeodomain-interacting protein kinase 1 , 2021, Bioengineered.

[10]  Kun Xu,et al.  Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. , 2021, Chemico-biological interactions.

[11]  Zhi-wei Wang,et al.  The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy , 2021, Molecular cancer.

[12]  Xiaohui Wang,et al.  c‐Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR‐145‐5p/SPOP/PD‐L1 axis , 2021, Clinical and translational medicine.

[13]  Jin-Moo Lee,et al.  Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells , 2021, International journal of molecular sciences.

[14]  J Zhang,et al.  Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis , 2021, BMC cancer.

[15]  M. Taheri,et al.  Role of lncRNA BANCR in Human Cancers: An Updated Review , 2021, Frontiers in Cell and Developmental Biology.

[16]  Wei Yang,et al.  miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1 , 2021, Cell Death & Disease.

[17]  Changping Wu,et al.  Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497/PD-L1 pathway. , 2021, Cellular signalling.

[18]  Lei Wang,et al.  LncRNA KCNQ1OT1 Secreted by Tumor Cell-Derived Exosomes Mediates Immune Escape in Colorectal Cancer by Regulating PD-L1 Ubiquitination via MiR-30a-5p/USP22 , 2021, Frontiers in Cell and Developmental Biology.

[19]  Jingbo Wang,et al.  MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3 , 2021, Cell death discovery.

[20]  Yan Li,et al.  miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer. , 2021, International immunopharmacology.

[21]  F. Slack,et al.  miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. , 2021, Cancer letters.

[22]  Xue-guang Zhang,et al.  Circular RNA hsa_circ_0003288 induces EMT and invasion by regulating hsa_circ_0003288/miR-145/PD-L1 axis in hepatocellular carcinoma , 2021, Cancer Cell International.

[23]  B. Baradaran,et al.  MicroRNA‐124‐3p suppresses PD‐L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling , 2021, Journal of cellular physiology.

[24]  H. M. El Tayebi,et al.  Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology. , 2021, Life sciences.

[25]  D. Geller,et al.  Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells , 2021, British Journal of Cancer.

[26]  M. Dinger,et al.  The Impact of Non-coding RNAs in the Epithelial to Mesenchymal Transition , 2021, Frontiers in Molecular Biosciences.

[27]  Min Zhang,et al.  LncRNA PROX1-AS1 Facilitates Gastric Cancer Progression via miR-877-5p/PD-L1 Axis , 2021, Cancer management and research.

[28]  Jun Ren,et al.  LncRNA SNHG1 regulates immune escape of renal cell carcinoma by targeting miR‐129‐3p to activate STAT3 and PD‐L1 , 2021, Cell biology international.

[29]  Kun Du,et al.  Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1 , 2021, Frontiers in Oncology.

[30]  Chinmoy Ghosh,et al.  A snapshot of the PD-1/PD-L1 pathway , 2021, Journal of Cancer.

[31]  Xiang Yu,et al.  HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis , 2021, Digestive Diseases and Sciences.

[32]  S. Zeng,et al.  miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells , 2021, Cancers.

[33]  Xiaoming Wang,et al.  LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway , 2021, Cancer Immunology, Immunotherapy.

[34]  F. Ning,et al.  The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells , 2021, Cancer communications.

[35]  Jing Liu,et al.  miR‑576‑3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD‑L1 and cyclin D1. , 2020, Molecular medicine reports.

[36]  Heng Zhang,et al.  Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer. , 2020, Translational research : the journal of laboratory and clinical medicine.

[37]  P. Dong,et al.  PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3 , 2020, Frontiers in Cell and Developmental Biology.

[38]  Ai-Jun Li,et al.  Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma , 2020, Hepatology International.

[39]  Ji Wang,et al.  LncRNA NUTM2A‐AS1 positively modulates TET1 and HIF‐1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR‐376a , 2020, Cancer medicine.

[40]  Tao Li,et al.  LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression , 2020, Genes & genomics.

[41]  Chengyi Sun,et al.  LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis , 2020, Journal of experimental & clinical cancer research : CR.

[42]  Hanshuo Zhang,et al.  miR-502-5p affects gastric cancer progression by targeting PD-L1 , 2020, Cancer Cell International.

[43]  B. Baradaran,et al.  Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway. , 2020, Life sciences.

[44]  Yun Liu,et al.  Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma , 2020, Reproductive Sciences.

[45]  M. Xue,et al.  Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC) , 2020, Journal of experimental & clinical cancer research : CR.

[46]  Kai Yin,et al.  LncRNA SNHG15 Contributes to Immuno-Escape of Gastric Cancer Through Targeting miR141/PD-L1 , 2020, OncoTargets and therapy.

[47]  Ce Li,et al.  PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR , 2020, Frontiers in Oncology.

[48]  Yanlv Ren,et al.  LncRNA GATA3‐AS1 facilitates tumour progression and immune escape in triple‐negative breast cancer through destabilization of GATA3 but stabilization of PD‐L1 , 2020, Cell proliferation.

[49]  W. Zhu,et al.  MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway , 2020, Clinical and Translational Oncology.

[50]  Min Zhang,et al.  MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment , 2020, Frontiers in Cell and Developmental Biology.

[51]  Ran Wei,et al.  Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective , 2020, Frontiers in Immunology.

[52]  Dong Li,et al.  Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells , 2020, Oncology research.

[53]  Li Li,et al.  Circular RNA circ_0000284 plays an oncogenic role in the progression of non-small cell lung cancer through the miR-377-3p-mediated PD-L1 promotion , 2020, Cancer Cell International.

[54]  R. Liu,et al.  Exosome-delivered miR-15a/16 target PD-L1 to inhibit immune escape in gastric cancer , 2020 .

[55]  J. Ji,et al.  MicroRNA‐155‐5p suppresses PD‐L1 expression in lung adenocarcinoma , 2020, FEBS open bio.

[56]  Meng Li,et al.  LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis , 2020, Cancer management and research.

[57]  Yuanting Gu,et al.  Cancer-associated fibroblasts-derived exosomes suppresses immune cell function in breast cancer via miR-92/PD-L1 pathway , 2020 .

[58]  Bahareh Yazdani,et al.  Fine-tuning ofroutine combined first- trimester screening: The ratio of serum-free- beta-human chorionic gonadotropin (fβ-hCG) to pregnancy-associated plasma protein-A (PAPP-A) could improve performance of Down syndrome screening program, a retrospective cohort study in Iran. , 2020, Human antibodies.

[59]  Yilin Chen,et al.  MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer , 2020, Cell biology international.

[60]  Jun Wang,et al.  MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma , 2020, Aging.

[61]  Jun Zhang,et al.  LINC00657 activates PD‐L1 to promote osteosarcoma metastasis via miR‐106a , 2020, Journal of cellular biochemistry.

[62]  Zhijun Wang,et al.  Cisplatin‐mediated down‐regulation of miR‐145 contributes to up‐regulation of PD‐L1 via the c‐Myc transcription factor in cisplatin‐resistant ovarian carcinoma cells , 2019, Clinical and experimental immunology.

[63]  Ye Kang,et al.  Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death‐ligand 1 by sponging microRNA‐195‐5p , 2019, Journal of cellular physiology.

[64]  G. Ji,et al.  miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1 , 2019, OncoTargets and therapy.

[65]  Bin Zhang,et al.  Polydatin Exerts an Antitumor Effect Through Regulating miR-382/PD-L1 Axis in Colorectal Cancer. , 2019, Cancer biotherapy & radiopharmaceuticals.

[66]  A. Naing,et al.  Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology , 2019, Clinical Cancer Research.

[67]  M. Otsuka,et al.  Expression of circular RNA CDR1‑AS in colon cancer cells increases cell surface PD‑L1 protein levels. , 2019, Oncology reports.

[68]  Y. Liu,et al.  LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint , 2019, Cell Death & Disease.

[69]  Guang-Yu Lian,et al.  LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. , 2019, Life sciences.

[70]  Meng Yang,et al.  miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death‐ligand 1 immune checkpoint , 2019, Experimental cell research.

[71]  Qi Zhou,et al.  A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling , 2019, Molecular Cancer.

[72]  Xiaomin Song,et al.  FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy , 2019, Front. Immunol..

[73]  Shuquan Wei,et al.  LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis , 2019, International journal of immunopathology and pharmacology.

[74]  X. Zhang,et al.  MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma , 2018, Journal of drug targeting.

[75]  J. Wan,et al.  miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway , 2018, Oncology reports.

[76]  Yun Wu,et al.  The miR‐3127‐5p/p‐STAT3 axis up‐regulates PD‐L1 inducing chemoresistance in non‐small‐cell lung cancer , 2018, Journal of cellular and molecular medicine.

[77]  Y. Lou,et al.  Next generation of immune checkpoint therapy in cancer: new developments and challenges , 2018, Journal of Hematology & Oncology.

[78]  Changping Wu,et al.  Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[79]  Yi Wang,et al.  miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1 , 2017, Biotechnology Letters.

[80]  Lei Wang,et al.  miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression , 2017, Oncotarget.

[81]  Zhenyi Xue,et al.  miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. , 2017, Biochemical and biophysical research communications.

[82]  Aiwu Zhou,et al.  Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade , 2017, Cell Discovery.

[83]  B. Spellberg,et al.  Type 1/Type 2 immunity in infectious diseases. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.